Genetics of Congenital Heart Disease

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorNationwide Children's Hospital

About this trial

Congenital heart disease (CHD) is the most common type of birth defect but the cause for the majority of cardiac birth defects remains unknown. Numerous epidemiologic studies have demonstrated evidence that genetic factors likely play a contributory, if not causative, role in CHD. While numerous genes have been identified by us and other investigators using traditional genetic approaches, these genes account for a minority of the non-syndromic CHDs. Therefore, we are now utilizing whole genome sequencing (WGS), with the addition of more traditional genetic techniques such as chromosomal microarray or traditional linkage analysis, to identify genetic causes of familial and isolated CHD. With WGS we are able to sequence all of the genetic material of an individual and apply different data analysis techniques based on whether we are analyzing a multiplex family or a cohort of trios (mother, father and child with CHD) with a specific isolated CHD. Therefore, WGS is a robust method for identification of novel genetic causes of CHD which will have important diagnostic and therapeutic consequences for these children.

Eligibility criteria

Qualifiers

Subjects must have a diagnosis of Congenital Heart Disease or be related to individuals with Congenital Heart Disease.

Disqualifiers

Healthy individuals unrelated to those with Congenital Heart Disease

Trial design

Treatments tested in this trial

  • Blood Sample Collection

Treatment groups

5,000 Participants
are divided into 1 treatment group

Sponsors and collaborators

Nationwide Children's Hospital

Lead sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator